Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
Hodi, F Stephen, Ballinger, Marcus, Lyons, Benjamin, Soria, Jean-Charles, Nishino, Mizuki, Tabernero, Josep, Powles, Thomas, Smith, David, Hoos, Axel, McKenna, Chris, Beyer, Ulrich, Rhee, Ina, Fine, Gregg, Winslow, Nathan, Chen, Daniel S, Wolchok, Jedd D
Published in Journal of clinical oncology (20.03.2018)
Published in Journal of clinical oncology (20.03.2018)
Get full text
Journal Article
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
Baylin, Stephen B, Vogelstein, Bert, Rhee, Ina, Bachman, Kurtis E, Park, Ben Ho, Jair, Kam-Wing, Yen, Ray-Whay Chiu, Schuebel, Kornel E, Cui, Hengmi, Feinberg, Andrew P, Lengauer, Christoph, Kinzler, Kenneth W
Published in Nature (London) (04.04.2002)
Published in Nature (London) (04.04.2002)
Get full text
Journal Article
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
Rizvi, Naiyer, Ademuyiwa, Foluso O, Cao, Z Alexander, Chen, Helen X, Ferris, Robert L, Goldberg, Sarah B, Hellmann, Matthew D, Mehra, Ranee, Rhee, Ina, Park, Jong Chul, Kluger, Harriet, Tawbi, Hussein, Sullivan, Ryan J
Published in Journal for immunotherapy of cancer (01.03.2023)
Published in Journal for immunotherapy of cancer (01.03.2023)
Get full text
Journal Article
De novo CpG island methylation in human cancer cells
Jair, Kam-Wing, Bachman, Kurtis E, Suzuki, Hiromu, Ting, Angela H, Rhee, Ina, Yen, Ray-Whay Chiu, Baylin, Stephen B, Schuebel, Kornel E
Published in Cancer research (Chicago, Ill.) (15.01.2006)
Published in Cancer research (Chicago, Ill.) (15.01.2006)
Get full text
Journal Article
CpG methylation is maintained in human cancer cells lacking DNMT1
Schuebel, Kornel E, Rhee, Ina, Jair, Kam-Wing, Yen, Ray-Whay Chiu, Lengauer, Christoph, Herman, James G, Kinzler, Kenneth W, Vogelstein, Bert, Baylin, Stephen B
Published in Nature (London) (27.04.2000)
Published in Nature (London) (27.04.2000)
Get full text
Journal Article
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Rojas, Luis A, Sethna, Zachary, Soares, Kevin C, Olcese, Cristina, Pang, Nan, Patterson, Erin, Lihm, Jayon, Ceglia, Nicholas, Guasp, Pablo, Chu, Alexander, Yu, Rebecca, Chandra, Adrienne Kaya, Waters, Theresa, Ruan, Jennifer, Amisaki, Masataka, Zebboudj, Abderezak, Odgerel, Zagaa, Payne, George, Derhovanessian, Evelyna, Müller, Felicitas, Rhee, Ina, Yadav, Mahesh, Dobrin, Anton, Sadelain, Michel, Łuksza, Marta, Cohen, Noah, Tang, Laura, Basturk, Olca, Gönen, Mithat, Katz, Seth, Do, Richard Kinh, Epstein, Andrew S, Momtaz, Parisa, Park, Wungki, Sugarman, Ryan, Varghese, Anna M, Won, Elizabeth, Desai, Avni, Wei, Alice C, D'Angelica, Michael I, Kingham, T Peter, Mellman, Ira, Merghoub, Taha, Wolchok, Jedd D, Sahin, Ugur, Türeci, Özlem, Greenbaum, Benjamin D, Jarnagin, William R, Drebin, Jeffrey, O'Reilly, Eileen M, Balachandran, Vinod P
Published in Nature (London) (01.06.2023)
Published in Nature (London) (01.06.2023)
Get full text
Journal Article
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Jung, Kyung Hae, LoRusso, Patricia, Burris, Howard, Gordon, Michael, Bang, Yung-Jue, Hellmann, Matthew D, Cervantes, Andrés, Ochoa de Olza, Maria, Marabelle, Aurelien, Hodi, F Stephen, Ahn, Myung-Ju, Emens, Leisha A, Barlesi, Fabrice, Hamid, Omid, Calvo, Emiliano, McDermott, David, Soliman, Hatem, Rhee, Ina, Lin, Ray, Pourmohamad, Tony, Suchomel, Julia, Tsuhako, Amy, Morrissey, Kari, Mahrus, Sami, Morley, Roland, Pirzkall, Andrea, Davis, S Lindsey
Published in Clinical cancer research (01.06.2019)
Published in Clinical cancer research (01.06.2019)
Get full text
Journal Article
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Kim, Tae Won, Burris, Howard A, de Miguel Luken, Maria J, Pishvaian, Michael J, Bang, Yung-Jue, Gordon, Michael, Awada, Ahmad, Camidge, D Ross, Hodi, F Stephen, McArthur, Grant A, Miller, Wilson H, Cervantes, Andres, Chow, Laura Q, Lesokhin, Alexander M, Rutten, Annemie, Sznol, Mario, Rishipathak, Deepali, Chen, Shang-Chiung, Stefanich, Eric, Pourmohamad, Tony, Anderson, Maria, Kim, Jeong, Huseni, Mahrukh, Rhee, Ina, Siu, Lillian L
Published in Clinical cancer research (15.08.2022)
Published in Clinical cancer research (15.08.2022)
Get full text
Journal Article
Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer
von Pawel, Joachim, Spigel, David R., Ervin, Thomas, Losonczy, György, Barlesi, Fabrice, Juhász, Erzsébet, Anderson, Maria, McCall, Bruce, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Reck, Martin
Published in The oncologist (Dayton, Ohio) (01.06.2018)
Published in The oncologist (Dayton, Ohio) (01.06.2018)
Get full text
Journal Article
암 치료를 위한 치료 조합
BERSAAS AUDUN TRYGGE HAUGEN, FREDRIKSEN AGNETE, GRANUM STINE, SCHJETNE KAROLINE, RHEE INA PARK, TORHAUG SIRI BRINCHMANN HANSEN
Year of Publication 01.12.2023
Get full text
Year of Publication 01.12.2023
Patent
Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer
García‐Carbonero, Rocío, van Cutsem, Eric, Rivera, Fernando, Jassem, Jacek, Gore, Ira, Tebbutt, Niall, Braiteh, Fadi, Argiles, Guillem, Wainberg, Zev A., Funke, Roel, Anderson, Maria, McCall, Bruce, Stroh, Mark, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Hurwitz, Herbert
Published in The oncologist (Dayton, Ohio) (01.04.2017)
Published in The oncologist (Dayton, Ohio) (01.04.2017)
Get full text
Journal Article
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Patients with Advanced Solid Tumors
Jung, Kyung Hae, LoRusso, Patricia, Burris, Howard, Gordon, Michael, Bang, Yung-Jue, Hellmann, Matthew D., Cervantes, Andrés, Ochoa de Olza, Maria, Marabelle, Aurelien, Hodi, F. Stephen, Ahn, Myung-Ju, Emens, Leisha A., Barlesi, Fabrice, Hamid, Omid, Calvo, Emiliano, McDermott, David, Soliman, Hatem, Rhee, Ina, Lin, Ray, Pourmohamad, Tony, Suchomel, Julia, Tsuhako, Amy, Morrissey, Kari, Mahrus, Sami, Morley, Roland, Pirzkall, Andrea, Davis, S. Lindsey
Published in Clinical cancer research (15.02.2019)
Published in Clinical cancer research (15.02.2019)
Get full text
Journal Article
Clinical translation of ferumoxytol‐based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population
Fredrickson, Jill, Serkova, Natalie J., Wyatt, Shelby K., Carano, Richard A.D., Pirzkall, Andrea, Rhee, Ina, Rosen, Lee S., Bessudo, Alberto, Weekes, Colin, de Crespigny, Alex
Published in Magnetic resonance in medicine (01.02.2017)
Published in Magnetic resonance in medicine (01.02.2017)
Get full text
Journal Article
Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer
García‐Carbonero, Rocío, van Cutsem, Eric, Rivera, Fernando, Jassem, Jacek, Gore, Ira, Tebbutt, Niall, Braiteh, Fadi, Argiles, Guillem, Wainberg, Zev A., Funke, Roel, Anderson, Maria, McCall, Bruce, Stroh, Mark, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Hurwitz, Herbert
Published in The oncologist (Dayton, Ohio) (01.10.2017)
Published in The oncologist (Dayton, Ohio) (01.10.2017)
Get full text
Journal Article
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
Weekes, Colin D., Rosen, Lee S., Capasso, Anna, Wong, Kit Man, Ye, Weilan, Anderson, Maria, McCall, Bruce, Fredrickson, Jill, Wakshull, Eric, Eppler, Steve, Shon-Nguyen, Quyen, Desai, Rupal, Huseni, Mahrukh, Hegde, Priti S., Pourmohamad, Tony, Rhee, Ina, Bessudo, Alberto
Published in Cancer chemotherapy and pharmacology (01.08.2018)
Published in Cancer chemotherapy and pharmacology (01.08.2018)
Get full text
Journal Article
Abstract CT097: A first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors
Hansen, Aaron R., Infante, Jeffrey R., McArthur, Grant, Gordon, Michael S., Lesokhin, Alexander M., Stayner, Ann-Lee, Bauer, Todd M., Sandhu, Shahneen, Tsai, Frank, Snyder, Alexandra, Subramaniam, Deepa S., Kim, Jeong, Stefanich, Eric, Li, Chi-Chung, Ruppel, Jane, Anderson, Maria, Gilbert, Houston, McCall, Bruce, Huseni, Mahrukh A., Rhee, Ina, Pishvaian, Michael
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Get full text
Journal Article
A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors
Infante, Jeffrey R., Hansen, Aaron Richard, Pishvaian, Michael J., Chow, Laura Quan Man, McArthur, Grant A., Bauer, Todd Michael, Liu, Stephen V., Sandhu, Shahneen Kaur, Tsai, Frank Yung-Chin, Kim, Jeong, Stefanich, Eric, Li, Chi-Chung, Gilbert, Houston, MCCALL, BRUCE, Anderson, Maria S., Huseni, Mahrukh, Rhee, Ina Park, Siu, Lillian L., Gordon, Michael S.
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
항-OX40 항체 및 PD-1 축 결합 길항제를 사용하여 암을 치료하는 방법
LI CHI CHUNG, HUSENI MAHRUKH, SUKUMARAN SID, STEFANICH ERIC, KIM JEONG, RHEE INA P
Year of Publication 09.03.2018
Get full text
Year of Publication 09.03.2018
Patent
항-OX40 항체를 이용한 암의 치료 방법
LI CHI CHUNG, HUSENI MAHRUKH, SUKUMARAN SID, STEFANICH ERIC, KIM JEONG, RHEE INA P
Year of Publication 02.02.2018
Get full text
Year of Publication 02.02.2018
Patent